OncRef

Clinical Trial: NCT02864992

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 2

Lead Sponsor:EMD Serono Research & Development Institute, Inc.
Information Provided By:EMD Serono
Last Update Posted:2026-07-14

Study Overview

Brief Summary

This study looked at how effective the study drug (tepotinib) was at stopping the growth and spread of lung cancer. This study also measures a number of other things including safety of the study drug and the side effects, how body processes the study drug, or how the study drug affects your quality of life. The study also has an optional pharmacogenetic research part. Pharmacogenetic research is an important way to try to understand the role of genetics in human disease and how genes impact the effectiveness of drugs, because differences in genes can change the way a person responds to a particular drug.

Official Title

A Phase II Single-arm Trial to Investigate Tepotinib in Advanced (Locally Advanced or Metastatic) Non-small Cell Lung Cancer With METex14 Skipping Alterations or MET Amplification (VISION)

Conditions

Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV

Intervention / Treatment

  • Drug: Tepotinib

Other Study ID Numbers

  • MS200095-0022
  • 2015-005696-24
  • 2024-512003-39-00
  • Japic CTI-163370
  • jRCT2080223315
  • CTR20192576
  • 2015

Start Date (Actual)

2016-09-13

Primary Completion Date (Actual)

2022-05-16

Study Completion Date (Estimated)

2026-08-31

Enrollment (Actual)

337

Study Type

Interventional

Phase

Phase 2